Cosmos Health Inc. - SIC # 5122 - DRUGS, DRUG PROPRIETARIES, AND DRUGGISTS SUNDRIES

Ticker Exchange SIC # Website Latest Ticker
COSM Nasdaq 5122 www.cosmoshealthinc.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cosmos Health Inc.

Cosmos Health CEO Greg Siokas Issues Letter to Shareholders Highlighting Record 2026 Revenue, U.S. Subscription Growth and Global Expansion - Oct 20th, 2026 10:15 am
Cosmos Health Provides Update on United States Business; Q4 2026 U.S. Revenue Expected to Reach $15 Million, with Gross Profit of $10.5 Million; Active U.S. Subscriptions Up 42% from 6,287 to 8,940 in Just Five Days - Oct 19th, 2026 7:30 am
Cosmos Health Reaches 6,287 Active U.S. Subscriptions, Substantially All Added Since Mid-September, with 60.5% of Online Checkout Orders Including a Subscription - Oct 14th, 2026 7:30 am
COSM US Growth Impresses - Oct 14th, 2026 6:28 am
Cosmos Health Reports Record Single-Day Direct-to-Consumer Sales in the United States Above $92,000, with $902,000 in Sales Over the Past 30 Days - Oct 13th, 2026 7:30 am
Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 Million - Oct 7th, 2026 7:30 am
COSM Continues to Surge Revenue Growth - Oct 7th, 2026 7:14 am
Cosmos Health's Brands Reach More Than 40 Countries Across Europe, the Middle East, North America and Asia, Addressing Global Markets Estimated at Approximately $946 Billion - Oct 1st, 2026 1:58 pm
COSM Continues to Grow Business - Sep 29th, 2026 11:03 am
Cosmos Health's CosmoFarm Reaches Record Annualized Revenue Above $60 Million, Up 4.3x Under Cosmos Health Ownership, as Robotics and AI Build Capacity to Support Over $100 Million in Annualized Revenue - Sep 29th, 2026 7:30 am
Cosmos Health's Contract Manufacturing Division Surpasses $20 Million in Implied Revenue and $18 Million in Implied Gross Profit Across Its Record 32.7 Million-Unit Production Pipeline - Sep 28th, 2026 6:00 am
Cosmos Health Adds 5.2 Million Units in New Five-Year Agreements with Target Pharma; Orderbook Surges Past 32.7 Million Units, Up 31% Since June - Sep 15th, 2026 8:30 am
Cosmos Health Moves to Tokenize CCX0722 Intellectual Property in Innovative Non-Dilutive Structure, Eyes $562 Billion Weight-Management Market - Sep 14th, 2026 1:59 pm
Cosmos Health Secures Additional 2.5 Million Units Under New Five-Year Contract Manufacturing Agreement with Viofar; Total Orderbook Surpasses 27.5 Million Units - Sep 11th, 2026 9:10 am
COSM Again Expands its Market and Accelerates its Growth - Sep 10th, 2026 6:11 am
Cosmos Health Launches C-ScrubVet in the UK, Advancing into the $69 Billion Global Animal Health Market - Sep 9th, 2026 7:30 am
Cosmos Health Strengthens Balance Sheet and Streamlines Capital Structure; Retires $8M ATW Convertible Note One Year Ahead of Maturity, Eliminating Further Dilution From Conversions - Aug 28th, 2026 7:30 am
Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories - Aug 24th, 2026 1:40 pm
Cosmos Health Enters Saudi Arabia Through Exclusive Distribution Agreement With Innova Healthcare; Secures Initial Purchase Order of 126,000 Sky Premium Life Units, With More Than 5 Million Units Expected Over Initial 5-Year Term - Aug 20th, 2026 7:30 am
Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Program Underway - Aug 19th, 2026 7:00 am